跳转至内容
Merck
CN
HomeWebinarsLentiviral Legends: Navigating the Complex Landscape of Lentiviral Vector Quality Control

Lentiviral Legends: Navigating the Complex Landscape of Lentiviral Vector Quality Control



WEBINAR

As the application of lentiviral (LV) vectors continues to expand, understanding the critical aspects of biosafety testing and quality control becomes paramount. This webinar explores the latest advancements in release testing of LV vectors, focusing on the key requirements for ensuring patient safety and therapeutic efficacy. You will gain insights into the regulatory landscape for performing release testing, including methodologies for the detection of RCL and for determining infectious titer. We will discuss challenges such as availability of sample volume and limited batches for qualification and introduce effective solutions to avoid unwelcome surprises and to expedite time to clinic. 

In this webinar, you will:

  • Gain familiarity with regulatory requirements for release testing of lentiviral vectors. 
  • Reflect on testing strategies for biosafety including detection of RCL and determination of infectious titer and how these techniques can enhance product safety and consistency.
  • Learn how to navigate quality control challenges and explore solutions for efficient testing processes that minimize time and material usage while ensuring therapeutic efficacy.

Speakers

Sarah Sheridan, Ph.D.

Sarah Sheridan, Ph.D.

Merck

Senior Technical Consultant

Dr Sarah Sheridan, Senior Technical Consultant at our company, provides scientific, technical and regulatory consultancy within the BioReliance® Biosafety Testing business. Drawing on over 30 years of experience in the biotech industry, Dr Sheridan provides biosafety testing consultancy for the company’s global client base to support pre-clinical to commercial phase biosafety testing of client manufactured products spanning monoclonal antibodies to vaccines and novel gene therapies. Dr Sheridan has a Ph.D. in Veterinary Virology from the University of Cambridge, UK and a B.Sc. Honours degree in Life Science.

Kenneth Jensen, Ph.D.

Kenneth Jensen, Ph.D.

Merck

Senior Scientist

Kenneth Jensen is a senior scientist supporting the virology operations team. For the past 5 years, Ken has supported cell and gene therapy release testing, serving as a subject matter expert focusing on replication-competent AAV and rAAV infectious titer testing. Prior to joining Merck, Ken worked at the NIH’s Integrated Research Facility supporting the 2014-2016 Ebola outbreak in Liberia and the PREVAIL and PREVAC Clinical Studies. Ken has a Ph.D. in virology from the University of Maryland.